Latest news

The latest information on our progress towards reaching our goals

07 August 2024

Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101

Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors

Read more

02 November 2023

Angiex Announces FDA Clearance of IND Application for AGX101
Read more

22 September 2023

Angiex focus on novel biology continues soaring to new heights in WSJ
Read more

29 September 2022

Angiex further bolsters its Executive Team with the appointment of Jason Sager, MD, as Chief Medical Officer
Read more

07 September 2022

Angiex Joins the Leaders in the Field of Antibody-Drug Conjugates at 13th Annual World ADC Meeting in San Diego
Read more

22 June 2022

Angiex welcomes Marty J. Duvall, our new CEO
Read more

18 August 2021

Angiex Completes $45 million Series B Financing to Advance Its TM4SF1 Antibody-Drug Conjugate toward Clinical Development
Read more

27 February 2020

Angiex Names Iain Dukes as Executive Chairman
Read more

26 January 2018

Agilent Awards Angiex with a Golden Ticket at LabCentral
Read more

28 August 2017

Millipore-Sigma collaborates with Angiex
Read more

14 March 2017

Angiex to perform research on International Space Station
Read more

Contact us

Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...

Get in touch